The feature that uniquely defines CML is a clone-specific BCR-ABL fusion gene that encodes an oncoprotein with constitutively elevated tyrosine kinase (TK) activity, driving the pathogenesis of the disease [4-6]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.